tiprankstipranks
Palvella Therapeutics, Inc. (PVLA)
NASDAQ:PVLA
US Market
PVLA
Palvella Therapeutics
RESEARCH TOOLSreports
Want to see PVLA full AI Analyst Report?

Palvella Therapeutics (PVLA) Stock Forecast & Price Target

800 Followers
See the Price Targets and Ratings of:

PVLA Analyst Ratings

Strong Buy
12Ratings
Strong Buy
12 Buy
0 Hold
0 Sell
Based on 12 analysts giving stock ratings to
Palvella
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

PVLA Stock 12 Month Forecast

Average Price Target

$232.67
▲(68.59% Upside)
Based on 12 Wall Street analysts offering 12 month price targets for Palvella Therapeutics in the last 3 months. The average price target is $232.67 with a high forecast of $270.00 and a low forecast of $205.00. The average price target represents a 68.59% change from the last price of $138.01.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"35":"$35","94":"$94","153":"$153","212":"$212","271":"$271"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":270,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$270.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":232.66666666666666,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$232.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":205,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$205.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[35,94,153,212,271],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,139.04,149.11384615384614,159.18769230769232,169.26153846153846,179.3353846153846,189.40923076923076,199.4830769230769,209.55692307692308,219.63076923076923,229.70461538461538,239.77846153846156,249.8523076923077,259.92615384615385,{"y":270,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,139.04,146.24205128205128,153.44410256410256,160.64615384615382,167.8482051282051,175.0502564102564,182.25230769230768,189.45435897435897,196.65641025641025,203.85846153846154,211.06051282051283,218.2625641025641,225.46461538461537,{"y":232.66666666666666,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,139.04,144.11384615384614,149.1876923076923,154.26153846153846,159.3353846153846,164.40923076923076,169.4830769230769,174.55692307692306,179.63076923076923,184.70461538461538,189.77846153846153,194.8523076923077,199.92615384615385,{"y":205,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":36.55,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52.71,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.23,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":79.84,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":94.53,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":104.67,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":79.9,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":132.61,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":120.38,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":126.84,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":112.59,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":138.26,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":139.04,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$270.00Average Price Target$232.67Lowest Price Target$205.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
LifeSci Capital Analyst forecast on PVLA
Sam Slutsky
LifeSci Capital
LifeSci Capital
$225→$236
Buy
71.00%
Upside
Reiterated
08/05/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Oppenheimer Analyst forecast on PVLA
Trevor Allred
Oppenheimer
Oppenheimer
$210
Buy
52.16%
Upside
Reiterated
08/05/26
Oppenheimer Reaffirms Their Buy Rating on Palvella Therapeutics (PVLA)
H.C. Wainwright Analyst forecast on PVLA
Andrew Fein
H.C. Wainwright
H.C. Wainwright
$270
Buy
95.64%
Upside
Reiterated
08/05/26
Analysts Are Bullish on Top Healthcare Stocks: Palvella Therapeutics (PVLA), Lifecore Biomedical (LFCR)
Canaccord Genuity Analyst forecast on PVLA
Whitney Ijem
Canaccord Genuity
Canaccord Genuity
$227→$232
Buy
68.10%
Upside
Reiterated
08/05/26
Palvella Therapeutics price target raised to $232 from $227 at CanaccordPalvella Therapeutics price target raised to $232 from $227 at Canaccord
Truist Financial Analyst forecast on PVLA
Danielle Brill
Truist Financial
Truist Financial
$210→$207
Buy
49.99%
Upside
Reiterated
08/05/26
Truist Financial Sticks to Its Buy Rating for Palvella Therapeutics (PVLA)
TD Cowen Analyst forecast on PVLA
Ritu Baral
TD Cowen
TD Cowen
$267
Buy
93.46%
Upside
Reiterated
08/04/26
Palvella Therapeutics: Strong Cash Runway and High-Confidence QTORIN Rapamycin Outlook Underpin New Buy Rating
BTIG Analyst forecast on PVLA
Jeet Mukherjee
BTIG
BTIG
$215
Buy
55.79%
Upside
Reiterated
08/04/26
Analysts Offer Insights on Healthcare Companies: Henry Schein (NASDAQ: HSIC), OrthoPediatrics (NASDAQ: KIDS) and Palvella Therapeutics (NASDAQ: PVLA)
Mizuho Securities Analyst forecast on PVLA
Graig Suvannavejh
Mizuho Securities
Mizuho Securities
$240
Buy
73.90%
Upside
Reiterated
07/01/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Bio-Techne (NASDAQ: TECH), Concentra Group Holdings Parent, Inc. (NYSE: CON) and Palvella Therapeutics (NASDAQ: PVLA)
Stifel Nicolaus Analyst forecast on PVLA
Annabel Samimy
Stifel Nicolaus
Stifel Nicolaus
$250
Buy
81.15%
Upside
Reiterated
06/24/26
Analysts Are Bullish on These Healthcare Stocks: Palvella Therapeutics (PVLA), Verastem (VSTM)
Craig-Hallum Analyst forecast on PVLA
Albert Lowe
Craig-Hallum
Craig-Hallum
$205
Buy
48.54%
Upside
Reiterated
06/22/26
Craig-Hallum Reaffirms Their Buy Rating on Palvella Therapeutics (PVLA)
Chardan Capital Analyst forecast on PVLA
Geulah Livshits
Chardan Capital
Chardan Capital
$240
Buy
73.90%
Upside
Reiterated
05/20/26
Chardan Capital Keeps Their Buy Rating on Palvella Therapeutics (PVLA)
Stephens Analyst forecast on PVLA
Sudan Loganathan
Stephens
Stephens
$220
Buy
59.41%
Upside
Initiated
05/11/26
Analyst Initiates Buy on Palvella Therapeutics, Citing Differentiated QTORIN Platform and $1B+ Long‑Term Revenue Potential
Clear Street Analyst forecast on PVLA
Kaveri Pohlman
Clear Street
Clear Street
$200→$220
Buy
59.41%
Upside
Reiterated
03/02/26
Palvella Therapeutics (PVLA) Receives a Buy from Clear Street
JonesTrading Analyst forecast on PVLA
Catherine Novack
JonesTrading
JonesTrading
$143→$209
Buy
51.44%
Upside
Reiterated
02/24/26
Palvella Therapeutics price target raised to $209 from $143 at JonesResearchPalvella Therapeutics price target raised to $209 from $143 at JonesResearch
Cantor Fitzgerald Analyst forecast on PVLA
Joshua Schimmer
Cantor Fitzgerald
Cantor Fitzgerald
$200→$210
Buy
52.16%
Upside
Reiterated
12/15/25
Palvella price target raised to $210 from $200 at Cantor FitzgeraldPalvella price target raised to $210 from $200 at Cantor Fitzgerald
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
LifeSci Capital Analyst forecast on PVLA
Sam Slutsky
LifeSci Capital
LifeSci Capital
$225→$236
Buy
71.00%
Upside
Reiterated
08/05/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Oppenheimer Analyst forecast on PVLA
Trevor Allred
Oppenheimer
Oppenheimer
$210
Buy
52.16%
Upside
Reiterated
08/05/26
Oppenheimer Reaffirms Their Buy Rating on Palvella Therapeutics (PVLA)
H.C. Wainwright Analyst forecast on PVLA
Andrew Fein
H.C. Wainwright
H.C. Wainwright
$270
Buy
95.64%
Upside
Reiterated
08/05/26
Analysts Are Bullish on Top Healthcare Stocks: Palvella Therapeutics (PVLA), Lifecore Biomedical (LFCR)
Canaccord Genuity Analyst forecast on PVLA
Whitney Ijem
Canaccord Genuity
Canaccord Genuity
$227→$232
Buy
68.10%
Upside
Reiterated
08/05/26
Palvella Therapeutics price target raised to $232 from $227 at CanaccordPalvella Therapeutics price target raised to $232 from $227 at Canaccord
Truist Financial Analyst forecast on PVLA
Danielle Brill
Truist Financial
Truist Financial
$210→$207
Buy
49.99%
Upside
Reiterated
08/05/26
Truist Financial Sticks to Its Buy Rating for Palvella Therapeutics (PVLA)
TD Cowen Analyst forecast on PVLA
Ritu Baral
TD Cowen
TD Cowen
$267
Buy
93.46%
Upside
Reiterated
08/04/26
Palvella Therapeutics: Strong Cash Runway and High-Confidence QTORIN Rapamycin Outlook Underpin New Buy Rating
BTIG Analyst forecast on PVLA
Jeet Mukherjee
BTIG
BTIG
$215
Buy
55.79%
Upside
Reiterated
08/04/26
Analysts Offer Insights on Healthcare Companies: Henry Schein (NASDAQ: HSIC), OrthoPediatrics (NASDAQ: KIDS) and Palvella Therapeutics (NASDAQ: PVLA)
Mizuho Securities Analyst forecast on PVLA
Graig Suvannavejh
Mizuho Securities
Mizuho Securities
$240
Buy
73.90%
Upside
Reiterated
07/01/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Bio-Techne (NASDAQ: TECH), Concentra Group Holdings Parent, Inc. (NYSE: CON) and Palvella Therapeutics (NASDAQ: PVLA)
Stifel Nicolaus Analyst forecast on PVLA
Annabel Samimy
Stifel Nicolaus
Stifel Nicolaus
$250
Buy
81.15%
Upside
Reiterated
06/24/26
Analysts Are Bullish on These Healthcare Stocks: Palvella Therapeutics (PVLA), Verastem (VSTM)
Craig-Hallum Analyst forecast on PVLA
Albert Lowe
Craig-Hallum
Craig-Hallum
$205
Buy
48.54%
Upside
Reiterated
06/22/26
Craig-Hallum Reaffirms Their Buy Rating on Palvella Therapeutics (PVLA)
Chardan Capital Analyst forecast on PVLA
Geulah Livshits
Chardan Capital
Chardan Capital
$240
Buy
73.90%
Upside
Reiterated
05/20/26
Chardan Capital Keeps Their Buy Rating on Palvella Therapeutics (PVLA)
Stephens Analyst forecast on PVLA
Sudan Loganathan
Stephens
Stephens
$220
Buy
59.41%
Upside
Initiated
05/11/26
Analyst Initiates Buy on Palvella Therapeutics, Citing Differentiated QTORIN Platform and $1B+ Long‑Term Revenue Potential
Clear Street Analyst forecast on PVLA
Kaveri Pohlman
Clear Street
Clear Street
$200→$220
Buy
59.41%
Upside
Reiterated
03/02/26
Palvella Therapeutics (PVLA) Receives a Buy from Clear Street
JonesTrading Analyst forecast on PVLA
Catherine Novack
JonesTrading
JonesTrading
$143→$209
Buy
51.44%
Upside
Reiterated
02/24/26
Palvella Therapeutics price target raised to $209 from $143 at JonesResearchPalvella Therapeutics price target raised to $209 from $143 at JonesResearch
Cantor Fitzgerald Analyst forecast on PVLA
Joshua Schimmer
Cantor Fitzgerald
Cantor Fitzgerald
$200→$210
Buy
52.16%
Upside
Reiterated
12/15/25
Palvella price target raised to $210 from $200 at Cantor FitzgeraldPalvella price target raised to $210 from $200 at Cantor Fitzgerald
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
AMLXAmylyx Pharmaceuticals Inc
TNYATenaya Therapeutics
JBIOJade Biosciences
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Palvella Therapeutics

3 Months
Andrew FeinH.C. Wainwright
Success Rate
15/16 ratings generated profit
94%
Average Return
+57.52%
Copying Andrew Fein's trades and holding each position for 3 Months would result in 93.75% of your transactions generating a profit, with an average return of +57.52% per trade.
1 Year
Andrew FeinH.C. Wainwright
Success Rate
16/16 ratings generated profit
100%
Average Return
+247.84%
Copying Andrew Fein's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +247.84% per trade.
2 Years
Andrew FeinH.C. Wainwright
Success Rate
16/16 ratings generated profit
100%
Average Return
+297.37%
Copying Andrew Fein's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +297.37% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

PVLA Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
36
32
28
28
17
Buy
2
2
1
2
4
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
38
34
29
30
21
In the current month, PVLA has received 21 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. PVLA average Analyst price target in the past 3 months is 232.67.
Each month's total comprises the sum of three months' worth of ratings.

PVLA Financial Forecast

PVLA Earnings Forecast

Next quarter’s earnings estimate for PVLA is -$1.77 with a range of -$2.31 to -$1.05. The previous quarter’s EPS was -$1.52. PVLA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 58.33% of the time in the same period. In the last calendar year PVLA has Performed in-line its overall industry.
Next quarter’s earnings estimate for PVLA is -$1.77 with a range of -$2.31 to -$1.05. The previous quarter’s EPS was -$1.52. PVLA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 58.33% of the time in the same period. In the last calendar year PVLA has Performed in-line its overall industry.

PVLA Sales Forecast

Next quarter’s sales forecast for PVLA is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were ―. PVLA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 66.67% of the time in the same period. In the last calendar year PVLA has Performed in-line its overall industry.
Next quarter’s sales forecast for PVLA is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were ―. PVLA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 66.67% of the time in the same period. In the last calendar year PVLA has Performed in-line its overall industry.

PVLA Stock Forecast FAQ

What is PVLA’s average 12-month price target, according to analysts?
Based on analyst ratings, Palvella Therapeutics, Inc.’s 12-month average price target is 232.67.
    What is PVLA’s upside potential, based on the analysts’ average price target?
    Palvella Therapeutics, Inc. has 68.59% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is PVLA a Buy, Sell or Hold?
          Palvella Therapeutics, Inc. has a consensus rating of Strong Buy which is based on 12 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Palvella Therapeutics, Inc.’s price target?
            The average price target for Palvella Therapeutics, Inc. is 232.67. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $270.00 ,the lowest forecast is $205.00. The average price target represents 68.59% Increase from the current price of $138.01.
              What do analysts say about Palvella Therapeutics, Inc.?
              Palvella Therapeutics, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 12 Wall Streets Analysts.
                How can I buy shares of PVLA?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.